BRAF Fusions (MSK, Cancer Discovery 2024) — Archer/Fusion Panel

Overview

MSK cohort of patients with oncogenic BRAF fusions detected by RNA-based fusion panel (MSK-Fusion/Archer) at Memorial Sloan Kettering Cancer Center between January 2014 and November 2022. This dataset captures fusion-panel confirmed BRAF fusions across 52 histologies and is deposited in cBioPortal as braf_msk_archer_2024. A companion tissue-sequenced cohort is available as braf_msk_impact_2024. PMID:38922339

Composition

  • 212 patients with oncogenic BRAF fusions (195 de novo, 17 detected post-targeted therapy; 15 confirmed acquired) across 52 histologies. PMID:38922339
  • 241 BRAF fusion-positive tumors total.
  • Cancer types include pilocytic astrocytoma, ganglioglioma, low-grade neuroepithelial tumors, acinar cell carcinoma of the pancreas, prostate adenocarcinoma, and colorectal cancer, among others. PMID:38922339
  • 24 patients with de novo BRAF fusions treated with MAPK-pathway directed therapies were evaluable for clinical outcomes (RECIST v1.1). PMID:38922339

Assays / panels (linked)

Papers using this cohort

  • PMID:38922339 — Tumor-agnostic genomic and clinical analysis of BRAF fusions identify actionable targets.

Notable findings derived from this cohort

  • De novo BRAF fusion prevalence was <1% (195/69,337 total patients screened) across all cancers; highest in pilocytic astrocytomas (56%, N=29). PMID:38922339
  • 82 unique 5’ fusion partners identified; 39 (48%) were novel. Most common: KIAA1549 (25%), SND1 (10%), AGK (6%). PMID:38922339
  • Fusion partner distribution was histology-specific: SND1 in prostate adenocarcinoma (21%), TRIM24 in colorectal cancer (43%). PMID:38922339
  • Of 20 evaluable patients treated with MAPK therapies: PR (N=2), SD (N=11), PD (N=7). PMID:38922339
  • 15 patients acquired BRAF fusions after targeted therapy; 10 had EGFR-mutant LUAD. PMID:38922339

Sources

This page was processed by crosslinker on 2026-05-04.